Martin O Weickert1, Gregory Kaltsas2, Dieter Hörsch3, Pablo Lapuerta4, Marianne Pavel5, Juan W Valle6, Martyn E Caplin7, Emily Bergsland8, Pamela L Kunz9, Lowell B Anthony10, Enrique Grande11, Kjell Öberg12, Staffan Welin12, Catherine Lombard-Bohas13, John K Ramage14, Ashwin Kittur4, Qi M Yang4, Matthew H Kulke15. 1. The ARDEN NET Centre, ENETS Centre of Excellence, University Hospitals Coventry and Warwickshire National Health Service Trust, Coventry, United Kingdom. Electronic address: martin.weickert@uhcw.nhs.uk. 2. The ARDEN NET Centre, ENETS Centre of Excellence, University Hospitals Coventry and Warwickshire National Health Service Trust, Coventry, United Kingdom. 3. Zentralklinik Bad Berka, Bad Berka, Germany. 4. Lexicon Pharmaceuticals Inc, The Woodlands, Texas. 5. Charité-Universitätsmedizin, Berlin, Germany; Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany. 6. University of Manchester/The Christie National Health Service Foundation Trust, Manchester, United Kingdom. 7. Neuroendocrine Tumour Unit, European Neuroendocrine Tumor Society Centre of Excellence, Royal Free Hospital, London, United Kingdom. 8. University of California, San Francisco, San Francisco, California. 9. Stanford University School of Medicine, Stanford, California. 10. University of Kentucky, Lexington, Kentucky. 11. MD Anderson International Cancer Center, Madrid, Spain. 12. Uppsala University Hospital, Uppsala, Sweden. 13. Hôpital Edouard Herriot, Hospices Civils de Lyon, Lyon, France. 14. King's Health Partners European Neuroendocrine Tumor Society Centre of Excellence, King's College Hospital, London, United Kingdom. 15. Dana-Farber Cancer Institute, Boston, Massachusetts.
Abstract
PURPOSE: In the placebo-controlled Phase III TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) trial, the oral tryptophan hydroxylase inhibitor telotristat ethyl significantly reduced bowel movement (BM) frequency during a 12-week, double-blind treatment period in 135 patients with metastatic neuroendocrine tumors with carcinoid syndrome and ≥4 BMs per day. Patients (mean [SD] age, 63.5 [8.9] years; mean [SD] body mass index, 24.9 [4.9] kg/m2) receivedplacebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg 3 times per day (TID) in addition to somatostatin analogue therapy. Weight loss is associated with uncontrolled carcinoid syndrome and may be associated with reduced survival. METHODS: Assessment of the occurrence of weight change ≥3% at week 12 was prespecified in the statistical analysis plan. FINDINGS: In 120 patients with weight data available, weight gain ≥3% was observed in 2 of 39 patients (5.1%) takingplacebo TID, 7 of 41 (17.1%) taking telotristat ethyl 250 mg TID, and 13 of 40 (32.5%) taking telotristat ethyl 500 mg TID (P = 0.0017) at week 12. Weight loss ≥3% was observed in 5 of 39 patients (12.8%) taking placebo TID, 4 of 41 (9.8%) taking telotristat ethyl 250 mg TID, and 6 of 40 (15.0%) taking telotristat ethyl 500 mg TID (P = 0.77). Biochemical and metabolic parameters of serum albumin and cholesterol significantly increased (P = 0.02 and P = 0.001, respectively) in patients gaining weight and decreased in patients who lost weight, suggesting an improvement in overall nutritional status. IMPLICATIONS: Up to 32.5% of patients treated with telotristat ethyl experienced significant, dose-dependent weight gain, associated with reduced diarrhea severity and improved biochemical and metabolic parameters. Improved nutritional status could be an additional aspect of telotristat ethyl efficacy among patients with functioning metastatic neuroendocrine tumors. ClinicalTrials.gov identifier: NCT01677910.
RCT Entities:
PURPOSE: In the placebo-controlled Phase III TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome) trial, the oral tryptophan hydroxylase inhibitor telotristat ethyl significantly reduced bowel movement (BM) frequency during a 12-week, double-blind treatment period in 135 patients with metastatic neuroendocrine tumors with carcinoid syndrome and ≥4 BMs per day. Patients (mean [SD] age, 63.5 [8.9] years; mean [SD] body mass index, 24.9 [4.9] kg/m2) received placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg 3 times per day (TID) in addition to somatostatin analogue therapy. Weight loss is associated with uncontrolled carcinoid syndrome and may be associated with reduced survival. METHODS: Assessment of the occurrence of weight change ≥3% at week 12 was prespecified in the statistical analysis plan. FINDINGS: In 120 patients with weight data available, weight gain ≥3% was observed in 2 of 39 patients (5.1%) taking placebo TID, 7 of 41 (17.1%) taking telotristat ethyl 250 mg TID, and 13 of 40 (32.5%) taking telotristat ethyl 500 mg TID (P = 0.0017) at week 12. Weight loss ≥3% was observed in 5 of 39 patients (12.8%) taking placebo TID, 4 of 41 (9.8%) taking telotristat ethyl 250 mg TID, and 6 of 40 (15.0%) taking telotristat ethyl 500 mg TID (P = 0.77). Biochemical and metabolic parameters of serum albumin and cholesterol significantly increased (P = 0.02 and P = 0.001, respectively) in patients gaining weight and decreased in patients who lost weight, suggesting an improvement in overall nutritional status. IMPLICATIONS: Up to 32.5% of patients treated with telotristat ethyl experienced significant, dose-dependent weight gain, associated with reduced diarrhea severity and improved biochemical and metabolic parameters. Improved nutritional status could be an additional aspect of telotristat ethyl efficacy among patients with functioning metastatic neuroendocrine tumors. ClinicalTrials.gov identifier: NCT01677910.
Authors: Jess G Fiedorowicz; Lisa Brown; James Li; Sagar V Parikh; Boadie W Dunlop; Brent P Forester; Richard C Shelton; Michael E Thase; Matthew Macaluso; Kunbo Yu; John F Greden Journal: Psychopharmacol Bull Date: 2021-11-03
Authors: Rosaria M Ruggeri; Barbara Altieri; Erika Grossrubatcher; Roberto Minotta; Maria Grazia Tarsitano; Virginia Zamponi; Andrea MIsidori; Antongiulio Faggiano; Anna Maria Colao Journal: Rev Endocr Metab Disord Date: 2022-03-16 Impact factor: 6.514
Authors: Martin A Walter; Cédric Nesti; Marko Spanjol; Attila Kollár; Lukas Bütikofer; Viktoria L Gloy; Rebecca A Dumont; Christian A Seiler; Emanuel R Christ; Piotr Radojewski; Matthias Briel; Reto M Kaderli Journal: Cochrane Database Syst Rev Date: 2021-11-25
Authors: Boris G Naraev; Magnus Halland; Daniel M Halperin; Amy J Purvis; Thomas M OʼDorisio; Thorvardur R Halfdanarson Journal: Pancreas Date: 2019-09 Impact factor: 3.327
Authors: Cristina Saavedra; Jorge Barriuso; Mairéad G McNamara; Juan W Valle; Angela Lamarca Journal: Cancer Manag Res Date: 2019-08-08 Impact factor: 3.989